Elite Pharmaceuticals Press Release for:

New Post Public Reply Private Reply Replies (2) Message Board
Couch ryan g #1230

Elite Pharmaceuticals Press Release for: Tuesday, April 23, 2013



ELITE PHARMACEUTICALS AWARDED SECOND U.S. PATENT FOR ABUSE RESISTANT DRUG FORMULATION

Northvale, New Jersey, Tuesday, April 23, 2013: Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) today announced the issuance of U.S. Patent No. 8,425,933 entitled “Abuse-Resistant Oral Dosage Forms and Method of Use Thereof” by the United States Patent and Trademark Office. This is the second issued U.S. patent covering Elite’s abuse resistant technology for opioid products. Elite has additional patents pending in the U.S., Canada and Europe.

"We are pleased to receive this second abuse resistant patent. The recent guidances and actions by the FDA related to extended release opioids and specifically oxycodone demonstrates the FDA support for abuse resistant technologies. Opioid products incorporating abuse resistant technologies have become a public health priority and these recent actions appear to be a major step towards the FDA eventually requiring that all extended release opioids utilize these technologies. This validates our approach and we believe substantially increases the value of our intellectual property and the abuse resistant products in our pipeline,” said Jerry Treppel, Elite’s Chairman and CEO. 

About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products to improve off-patent drug products and developing generic versions of controlled release drug products with high barriers to entry. Elite has three commercial products currently being sold, three additional products approved and soon to be launched, and one additional product pending approval by the FDA. Elite’s lead pipeline products include abuse resistant opioids utilizing the Company’s patented proprietary technology, and a once-daily opioid. They are sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also provides contract manufacturing for Actavis and Ascend Laboratories (previously a subsidiary of ThePharmaNetwork and now a subsidiary of Alkem Laboratories Ltd.) and has partnered with Mikah Pharma to develop a new product, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the United States market and its territories. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.


Contact:
Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com


This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Including those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release, readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, delays, uncertainties, inability to obtain necessary ingredients and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements These risks and other factors, including, without limitation, the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, intellectual property protections and defenses, and the Company’s ability to operate as a going concern, are discussed in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q and 8-K. Elite undertakes no obligation to update any forward-looking statements.


Elite Pharmaceuticals Inc (ELTP) Stock Research Links

ELTP Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 31

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 82

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
West Virginia SEO Timelines Demand Patience, Not Hype

Updated Category News Views 68

A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...

Continue Reading
1031 Specialists Takes Tax Deferral to Public TV

Updated Category News Views 100

A tax rule most people ignore is getting a television spotlight. 1031 Specialists says it will appear on All Access with Andy Garcia, an educational series distributed to Public Television stations nationwide, to explain the 1031 exchange and its role in real estate investing. That is a sensible bit of exposure for a niche business built around a topic investors tend to...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 5

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 44

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Surfcomber Uses Art Week to Deepen Its Guest Appeal

Updated Category News Views 70

Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...

Continue Reading
Sivers Moves Q3 Release to Accommodate U.S. Investors

Updated Category News Views 74

Thanksgiving has a nasty habit of turning perfectly ordinary earnings dates into ghost towns, and Sivers Semiconductors has sensibly stepped around that pothole. The company will publish its third-quarter 2026 interim report on Monday, November 30, rather than Thursday, November 26. That is not a strategy reset, a warning, or some grand corporate mystery. It is a calendar...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 103

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
Africa Tech Festival Puts Trust Ahead of AI Hype Cycle

Updated Category News Views 75

Fifteen thousand people can fill a convention centre, but they cannot magically deliver a package, fund a small business, or repair harm from a bad automated decision. That rather useful dose of reality ran through the final day of Africa Tech Festival 2026 in Cape Town. The 29th edition drew more than 15,000 delegates across three days, and the strongest message was not...

Continue Reading

Top 5 Most Recently Viewed Articles

Long-Term Efficacy of FINTEPLA in Managing Lennox-Gastaut Syndrome

Updated Category News Views 124

Long-Term Efficacy of FINTEPLA in Managing Lennox-Gastaut Syndrome FINTEPLA, known scientifically as fenfluramine, has demonstrated remarkable potential in treating seizures associated with Lennox-Gastaut syndrome (LGS) as confirmed by a significant open-label extension (OLE) study. This study emphasized the drug's beneficial effects, particularly in lowering seizure...

Continue Reading
Implications of U.S. Withdrawal from the Paris Agreement

Updated Category News Views 370

Significance of the U.S. Withdrawal from the Paris Agreement The decision by the U.S. to withdraw from the Paris Agreement is a critical moment not just for America, but for the entire globe. Analysts and climate diplomats suggest that this move will have far-reaching consequences, more profound than those witnessed during the initial exit in recent years. Accelerating...

Continue Reading
Ambarella's Oculii AI Technology Enhances Lotus Electric Vehicles

Updated Category News Views 236

Ambarella's Oculii AI Radar Transforms Lotus Vehicles In a major technological breakthrough, Ambarella has announced the worldwide rollout of its Oculii™ AI 4D imaging radar technology in Lotus's 2023 and 2024 electric vehicles. This advanced technology is integrated into the eye-catching Lotus Eletre electric hyper-SUV and the thrilling Lotus Emeya hyper-GT models....

Continue Reading
Luxury Brands Adapt to Broader Market with Affordable Options

Updated Category News Views 355

Luxury Brands Embrace Affordability for Wider Appeal In recent times, luxury brands have found themselves in a challenging position. With diminishing demand for high-priced items like $3,000 handbags and $4,000 cashmere jackets, many luxury labels are shifting their focus. They are creating a wider array of products targeting the middle-class customer, including...

Continue Reading
Elife Group's Game-Changing Platform for Global Transport Solutions

Updated Category News Views 328

Elife Group Launches Revolutionary Multi-Modal Travel Platform Elife Group has introduced an innovative multi-modal platform that redefines ground transportation. By seamlessly integrating rail and ride-hailing services into a single platform, they have created a comprehensive solution for travelers seeking convenient and efficient options. This strategic move positions...

Continue Reading